Verve Therapeutics (NASDAQ:VERV) Rating Increased to Overweight at Cantor Fitzgerald

Verve Therapeutics (NASDAQ:VERV) was upgraded by research analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a note issued to investors on Tuesday, Marketbeat reports.

A number of other equities research analysts have also weighed in on VERV. Canaccord Genuity Group lifted their target price on Verve Therapeutics from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Tuesday. Royal Bank of Canada decreased their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. HC Wainwright increased their target price on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Monday. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Finally, Guggenheim reiterated a “buy” rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.75.

Verve Therapeutics Price Performance

VERV stock opened at $4.51 on Tuesday. Verve Therapeutics has a 12 month low of $2.86 and a 12 month high of $9.31. The firm’s 50-day moving average is $5.76 and its 200 day moving average is $5.91. The company has a market capitalization of $400.47 million, a PE ratio of -1.83 and a beta of 1.86.

Verve Therapeutics (NASDAQ:VERV) last issued its earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Sell-side analysts forecast that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Institutional Trading of Verve Therapeutics

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of Verve Therapeutics by 189.7% during the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after acquiring an additional 3,964 shares in the last quarter. IFP Advisors Inc grew its holdings in Verve Therapeutics by 823,700.0% in the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after purchasing an additional 8,237 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Verve Therapeutics in the fourth quarter worth $50,000. KFG Wealth Management LLC acquired a new position in shares of Verve Therapeutics during the first quarter worth $46,000. Finally, Impact Partnership Wealth LLC purchased a new stake in shares of Verve Therapeutics during the 4th quarter valued at $70,000. 97.11% of the stock is currently owned by institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.